Article Text
Statistics from Altmetric.com
Recurrent pericarditis is one of the most troublesome complications of pericarditis, affecting 15%–30% of patients with a first episode of pericarditis1 2 and often severely affecting the quality of life of patients. Colchicine has been demonstrated to be a safe and efficacious treatment to halve the recurrence rate either in acute or recurrent episodes at 18 months also after drug withdrawal after 3–6 months of therapy,1 2 and it is a mainstay of medical therapy in association with non-steroidal anti-inflammatory drugs and/or corticosteroids at low to moderate doses3 according to 2015 European Society of Cardiology guidelines with a class IA indication.4 However, 5%–10% of patients with recurrent pericarditis cannot achieve disease control with a combination of these therapies and may become corticosteroid-dependent and colchicine resistant, often with significant side effects related to the chronic use of corticosteroids.5 For these patients, new therapies are needed beyond traditional approaches, and anti-interleukin (IL)-1 agents, such as rilonacept, have been recently proposed as new drugs in this clinical setting.
The current paper6 reports an open-label, single-arm, phase II study evaluating the efficacy and safety of rilonacept in 25 adult patients (mean age 43 years, 60% women) with idiopathic or postpericardiotomy recurrent pericarditis with a least two recurrences and active disease or corticosteroid dependence evaluated at nine sites in the USA from January 2018 to May 2019. Rilonacept is an IL-1 trap active on either IL-1-α and IL-1-β, and was given subcutaneously with a loading dose of 320 mg for the first day followed by a maintenance dose of 160 mg weekly for 6 weeks and extended to an optional time of 18 weeks (total treatment time of 6 months).
A single dose of rilonacept was able to reduce either pericarditis pain or C reactive protein (CRP) with a median normalisation …
Footnotes
Contributors MI confirmed that the paper is original and approved for submission. MI is the sole author of this editorial.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests MI has been advisory board member for Sobi and Kiniksa.
Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.
Patient consent for publication Not required.
Linked Articles
- Heart failure and cardiomyopathies